Trade-Ideas LLC identified

Nevro

(

NVRO

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Nevro as such a stock due to the following factors:

  • NVRO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $28.8 million.
  • NVRO has traded 1,296 shares today.
  • NVRO is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NVRO with the Ticky from Trade-Ideas. See the FREE profile for NVRO NOW at Trade-Ideas

More details on NVRO:

Nevro Corp., a medical device company, develops and commercializes a neuromodulation platform for the treatment of chronic pain in the United States, Europe, and Australia. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy. Currently there are 8 analysts that rate Nevro a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Nevro has been 520,600 shares per day over the past 30 days. Nevro has a market cap of $2.3 billion and is part of the health care sector and health services industry. Shares are up 18.7% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Nevro as a

sell

. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

Highlights from the ratings report include:

  • Net operating cash flow has significantly decreased to -$30.27 million or 79.83% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Health Care Equipment & Supplies industry average, but is greater than that of the S&P 500. The net income increased by 33.9% when compared to the same quarter one year prior, rising from -$14.06 million to -$9.29 million.
  • NEVRO CORP has improved earnings per share by 42.1% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, NEVRO CORP reported poor results of -$2.55 versus -$0.68 in the prior year. This year, the market expects an improvement in earnings (-$1.73 versus -$2.55).
  • Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, NEVRO CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for NEVRO CORP is rather high; currently it is at 63.30%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -22.29% is in-line with the industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.